The abstract is read at the publisher; the summary is JClub's.
In an open-label phase 2 trial in relapsed or refractory large B-cell lymphoma, prophylactic emapalumab before axi-cel did not prevent refractory high-grade ICANS/CRS-IEC-HS despite CAR T-cell expansion exceeding ZUMA-1 and a local standard-of-care cohort.
- Why it matters: CRS and ICANS are common with axi-cel, and preclinical work suggested IFN-γ blockade might reduce toxicity without harming efficacy; this trial tested that premise in patients.
- What they did: The study gave single-dose emapalumab one day before axi-cel (NCT06550141) and monitored toxicity severity, cytokine markers, and CAR T-cell expansion in the first two enrolled patients.
- The result: Both patients developed treatment-refractory overlapping CRS-IEC-HS with high-grade ICANS requiring multiple immunomodulatory agents, while IL-2 and sIL-2R stayed markedly elevated; complete responses occurred, but recruitment was stopped and the protocol amended.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.